ClinicalTrials.gg
RecruitingNCT07622186Updated Sep 2, 2026

A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of SKB571 for injection and Osimertinib in Non-Small Cell Lung Cancer, sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. Recruiting at 27 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (part of Sichuan Kelun Pharmaceutical Co.,Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China — 763 open to participants now, 987 under way, 203 of them phase 3. Carcinoma, Non-Small-Cell Lung · China.

Planned enrollment
622nd of 1,593
150 · median 100
Started
2026
with 190 others
Phase 2
650 of 1,880
273 open now
Primary completion
2028-12
later than 832 of 986 live
Registered
1,782nd of 1,880
by date

Among the 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China, this one is the 622nd largest by planned enrollment of the 1,593 interventional ones that give a count, is one of 191 that started in 2026, is one of 650 in phase 2, reaches primary completion later than 832 of the 986 other live ones, and was the 1,782nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

763 of the 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China are open now. Recruiting first, the newest first:

758 more — sign in →

All 763 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China, or all of them as a file.
02

Study summary

This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB571 Combination Therapy in participants with Non-Small Cell Lung Cancer (NSCLC).

Read the detailed description

This is a multicenter, open-label, Phase II clinical study to evaluate the efficacy, safety, tolerability, PK characteristics, and immunogenicity of SKB571Combination Therapy in participants with Non-Small Cell Lung Cancer (NSCLC). Approximately 150 subjects will be enrolled in this study, including 3 cohorts.

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, age ≥ 18 years and ≤ 75 years at the time of signing the form (ICF).
  2. Participants must have or cytologically confirmed non-small cell lung cancer (NSCLC).
  3. At least one as assessed by the investigator according to v1.1.
  4. (ECOG) performance status of 0 or 1.
  5. ≥ 12 weeks as assessed by the investigator.
  6. Adequate organ and bone marrow function.
  7. Male and female participants must agree to use highly effective methods of during the study treatment period.
  8. Participants must voluntarily join this study, sign the ICF, and be able to comply with the visits and related procedures specified in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Participants with other malignant tumors within 3 years before the first dose of study treatment.
  2. Active or untreated central nervous system (CNS) .
  3. Current uncontrolled concomitant diseases
  4. Clinically severe lung damage due to complications of lung disorder
  5. Participants with a history of interstitial lung disease (ILD)/non-infectious pneumonitis
  6. A history of severe skin diseases
  7. Unresolved toxicity from prior anti-tumor therapy
  8. Serious infection within 4 weeks before the first dose of study treatment
  9. Known active pulmonary tuberculosis.
  10. Participants who have undergone major surgery or had severe trauma within 4 weeks before the first dose, or are expected to require major surgery during the study.
  11. Known history of allogeneic organ transplant or hematopoietic stem cell transplant.
  12. Pregnant or breastfeeding women.
  13. Other conditions deemed by the investigator as unsuitable for participation in this clinical trial.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    NSCLC with sensitive EGFR mutations

    Drug: SKB571 for injection · Drug: Osimertinib · Drug: Furmonertinib

  • Experimental
    NSCLC with EGFR wild-type

    Drug: SKB571 for injection · Drug: carboplatin · Drug: Cisplatin · Drug: Pembrolizumab

  • Experimental
    NSCLC with uncommon EGFR mutations

    Drug: SKB571 for injection · Drug: Furmonertinib · Drug: carboplatin · Drug: Cisplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    Time frame: Up to approximately 36 months

Secondary outcomes

  1. Progression-free survival (PFS), duration of response (DOR), disease control rate (DCR), and overall survival (OS)

    Time frame: Up to approximately 36 months

  2. Safety and tolerability

    Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (based on CTCAE v6.0), clinically significant abnormal laboratory test results, etc.

    Time frame: Up to approximately 36 months

  3. Maximum Plasma Concentration (Cmax) of SKB571-ADC

    Blood Samples will be collected to determine the Cmax of SKB571-ADC in the plasma

    Time frame: Up to approximately 36 months

  4. Immunogenicity

    Blood Samples will be collected to measure Anti-drug antibody (ADA) against SKB571 in the serum

    Time frame: Up to approximately 36 months

  5. Minimum Plasma Concentration(Cmin) of SKB571-ADC

    Blood samples will be collected to determine the Cmin of SKB571-ADC in the plasma

    Time frame: Up to approximately 36 months

  6. Maximum Plasma Concentration(Cmax) of SKB571-TAb

    Blood samples will be collected to determine the Cmax of SKB571-TAb in the plasma

    Time frame: Up to approximately 36 months

  7. Minimum Plasma Concentration(Cmin) of SKB571-TAb

    Blood Samples will be collected to determine the Cmin of SKB571-TAb in the plasma

    Time frame: Up to approximately 36 months

  8. Maximum Plasma Concentration (Cmax) of unconjugated KL610348

    Blood Samples will be collected to determine the Cmax of unconjugated KL610348 in the plasma

    Time frame: Up to approximately 36 months

  9. Minimum Plasma Concentration(Cmin) of unconjugated KL610348

    Blood Samples will be collected to determine the Cmin of unconjugated KL610348 in the plasma

    Time frame: Up to approximately 36 months

Other outcomes

  1. Correlation between biomarkers and efficacy

    To evaluate the correlation between the expression levels of tumor-related genes in tumor tissues and efficacy

    Time frame: Up to approximately 36 months

07

Study locations

2 of 27 sites recruiting
  • Peking University Cancer Hospital
    Beijing, Beijing Municipality 100142, China
    Not yet recruiting
    • Jian Fang · Principal investigator
  • Xinqiao Hospital of Army Medical University
    Chongqing, Chongqing Municipality 400037, China
    Not yet recruiting
    • Zhi Xu · Principal investigator
  • Fujian Provincial Cancer Hospital
    Fuzhou, Fujian 350014, China
    Not yet recruiting
    • Jing Zhang · Principal investigator
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361003, China
    Not yet recruiting
    • Jingxun Wu · Principal investigator
  • Dongguan People's Hospital
    Dongguan, Guangdong 523018, China
    Not yet recruiting
    • Guanming Jiang · Principal investigator
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510060, China
    Recruiting
    • Li Zhang · Principal investigator
  • Guangzhou Medical University First Affiliated Hospital
    Guangzhou, Guangdong 510120, China
    Recruiting
    • Chengzhi Zhou · Principal investigator
  • Guilin Medical University First Affiliated Hospital
    Guilin, Guangxi 541001, China
    Not yet recruiting
    • Yanyi Zhao · Principal investigator
  • Guangxi Medical University Affiliated Tumor Hospital
    Nanning, Guangxi 530021, China
    Not yet recruiting
    • Yun Zhao · Principal investigator
    • Qitao Yu · Principal investigator
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150081, China
    Not yet recruiting
    • Yan Yu · Principal investigator
    • Qingwei Meng · Principal investigator
  • Henan Cancer Hospital
    Zhengzhou, Henan 450008, China
    Not yet recruiting
    • Qiming Wang · Principal investigator
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
    Not yet recruiting
    • Siyuan Huang · Principal investigator
  • Xiangyang Central Hospital
    Xiangyang, Hubei 441021, China
    Not yet recruiting
    • Tienan Yi · Principal investigator
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
    Not yet recruiting
    • Bolin Chen · Principal investigator
    • Xingxiang Pu · Principal investigator
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
    Not yet recruiting
    • Wangjian Zha · Principal investigator
  • Jiangxi Cancer Hospital
    Nanchang, Jiangxi 330029, China
    Not yet recruiting
    • Zhentian Liu · Principal investigator
  • Jilin Cancer Hospital
    Changchun, Jilin 130012, China
    Not yet recruiting
    • Haifeng Liu · Principal investigator
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning 110004, China
    Not yet recruiting
    • Wei Zheng · Principal investigator
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
    Not yet recruiting
    • Haiyong Wang · Principal investigator
    • Yan Zhang · Principal investigator
  • Shanxi Cancer Hospital
    Taiyuan, Shanxi 030013, China
    Not yet recruiting
    • Wei Guo · Principal investigator
  • The First Affiliated Hospital of Xi'an Jiao Tong University
    Xi’an, Shanxi 710061, China
    Not yet recruiting
    • Yu Yao · Principal investigator
  • Sichuan Cancer Hospital & Institute
    Chengdu, Sichuan 610041, China
    Not yet recruiting
    • Wenxiu Yao · Principal investigator
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
    Not yet recruiting
    • Guowei Che · Principal investigator
  • Tianjin Cancer Hospital
    Tianjin, Tianjin Municipality 300060, China
    Not yet recruiting
    • Liuchun Wang · Principal investigator
  • Xinjiang Medical University Affiliated Tumor Hospital
    Ürümqi, Xinjiang Uygur Autonomous Region 830011, China
    Not yet recruiting
    • Chunling Liu · Principal investigator
  • Yunnan Cancer Hospital
    Kunming, Yunnan 650118, China
    Not yet recruiting
    • Runxiang Yang · Principal investigator
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
    Not yet recruiting
    • Xinmin Yu · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2028, 29 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 29 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2026
First posted
Jun 3, 2026
StartActual
Jul 15, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2029
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07622186
Responsible party
Sponsor
First posted
Jun 3, 2026
Start date
Jul 15, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Sep 2, 2026

Study contacts

Xin Li, MD
Contact
lixin@kelun.com
86-13311373861
Xin Li, MD
study director · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SKB571

Start the discussion